DEVELOPING AN AGILE SYSTEM FOR CONTINUOUS CGMP MANUFACTURING OF STERILE LIQUID (INJECTABLE AND INHALATION) PRODUCTS

Continuous manufacturing is widely established and commercialized for small-molecule oral solid doses and API synthesis, but its application to sterile liquid drug products remains largely limited to biologics, where it is mostly limited to the synthesis and purification of the active substance. This gap became critical during the COVID-19 pandemic when severe shortages of essential injectable medications exposed limitations in manufacturing capacity and supply chain resilience. The main aim of this dissertation is to design, develop and evaluate an agile continuous manufacturing platform for sterile liquid formulations, demonstrated using bupivacaine hydrochloride injection and albuterol sulfate inhalation solution. The platform was developed using Quality by Design principles to support flexible, scalable, and controlled manufacture of sterile liquid formulations. It integrates real-time quality control and features a process module designed for continuous compounding and aseptic fill-finish operations. The manufacturing process comprises feeding bags containing solutions of formulation ingredients, pumped continuously at controlled flowrates, combined in a manifold and further homogenized using a static mixer. The resulting formulation passes through an inline sensor block that measures pH, conductivity, and active pharmaceutical ingredient concentration in real time. These measurements are integrated into a DeltaV-based automation and process-control system that continuously evaluates product conformance against predefined specification limits. The control architecture incorporates sensors, process analytical technology, automated alarms, electronic process historian, and MPC based control adjustments to maintain a defined state of control. Continuous monitoring focuses on formulation related critical quality attributes (CQAs) and critical process parameters (CPPs), including active pharmaceutical ingredient (API) concentration, pH, and conductivity (as an in-process surrogate for ionic strength and tonicity). The process is designed to enable immediate identification and segregation of potentially nonconforming, out-of-specification (OOS) material. A risk-based assessment was performed to identify critical material attributes and critical process parameters with the greatest potential impact on product quality, thereby supporting process understanding, risk mitigation, and continual improvement. Drug-product quality was evaluated through assay, pH, osmolality, sterility, container closure integrity and stability testing. These assessments verified that critical quality attributes including API concentration, pH, conductivity/tonicity, and sterility met predefined specifications and were maintained through continuous formulation, sterilizing filtration, aseptic fill–finish, and storage. This platform enables manufacturers to switch production to a different drug product with different dosage strength, thereby making the system flexible and agile. Such agile solutions are getting widely adopted by the pharmaceutical industry since they respond rapidly to shortages by changing the scale of production based on requirements, enable small scale production of specialized medicine by making it economically viable, and eliminate massive footprint by fitting continuous lines into single rooms, thereby reducing operating expenditure. This work demonstrates the feasibility of applying continuous manufacturing principles to sterile liquid products. By integrating continuous compounding, real-time quality control, automated diversion, sterilizing filtration, aseptic transfer, and automated fill–finish within a DeltaV controlled cGMP platform, this dissertation establishes a practical foundation for more agile, scalable, and resilient manufacture of critical sterile liquid medicines.

Authors

Publication Details

Journal
Rutgers University Community Repository (Rutgers University)
Published
2026-11-17
DOI
https://doi.org/10.7282/t3-v187-9k74
Primary Topic
Granular flow and fluidized beds
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

DEVELOPING AN AGILE SYSTEM FOR CONTINUOUS CGMP MANUFACTURING OF STERILE LIQUID (INJECTABLE AND INHALATION) PRODUCTS

Priya Das
Rutgers University Community Repository (Rutgers University)
Granular flow and fluidized beds
article

DEVELOPING AN AGILE SYSTEM FOR CONTINUOUS CGMP MANUFACTURING OF STERILE LIQUID (INJECTABLE AND INHALATION) PRODUCTS

Priya Das
article en

Abstract

Continuous manufacturing is widely established and commercialized for small-molecule oral solid doses and API synthesis, but its application to sterile liquid drug products remains largely limited to biologics, where it is mostly limited to the synthesis and purification of the active substance. This gap became critical during the COVID-19 pandemic when severe shortages of essential injectable medications exposed limitations in manufacturing capacity and supply chain resilience. The main aim of this dissertation is to design, develop and evaluate an agile continuous manufacturing platform for sterile liquid formulations, demonstrated using bupivacaine hydrochloride injection and albuterol sulfate inhalation solution. The platform was developed using Quality by Design principles to support flexible, scalable, and controlled manufacture of sterile liquid formulations. It integrates real-time quality control and features a process module designed for continuous compounding and aseptic fill-finish operations. The manufacturing process comprises feeding bags containing solutions of formulation ingredients, pumped continuously at controlled flowrates, combined in a manifold and further homogenized using a static mixer. The resulting formulation passes through an inline sensor block that measures pH, conductivity, and active pharmaceutical ingredient concentration in real time. These measurements are integrated into a DeltaV-based automation and process-control system that continuously evaluates product conformance against predefined specification limits. The control architecture incorporates sensors, process analytical technology, automated alarms, electronic process historian, and MPC based control adjustments to maintain a defined state of control. Continuous monitoring focuses on formulation related critical quality attributes (CQAs) and critical process parameters (CPPs), including active pharmaceutical ingredient (API) concentration, pH, and conductivity (as an in-process surrogate for ionic strength and tonicity). The process is designed to enable immediate identification and segregation of potentially nonconforming, out-of-specification (OOS) material. A risk-based assessment was performed to identify critical material attributes and critical process parameters with the greatest potential impact on product quality, thereby supporting process understanding, risk mitigation, and continual improvement. Drug-product quality was evaluated through assay, pH, osmolality, sterility, container closure integrity and stability testing. These assessments verified that critical quality attributes including API concentration, pH, conductivity/tonicity, and sterility met predefined specifications and were maintained through continuous formulation, sterilizing filtration, aseptic fill–finish, and storage. This platform enables manufacturers to switch production to a different drug product with different dosage strength, thereby making the system flexible and agile. Such agile solutions are getting widely adopted by the pharmaceutical industry since they respond rapidly to shortages by changing the scale of production based on requirements, enable small scale production of specialized medicine by making it economically viable, and eliminate massive footprint by fitting continuous lines into single rooms, thereby reducing operating expenditure. This work demonstrates the feasibility of applying continuous manufacturing principles to sterile liquid products. By integrating continuous compounding, real-time quality control, automated diversion, sterilizing filtration, aseptic transfer, and automated fill–finish within a DeltaV controlled cGMP platform, this dissertation establishes a practical foundation for more agile, scalable, and resilient manufacture of critical sterile liquid medicines.

Rutgers University Community Repository (Rutgers University)
Good health and well-being, Industry, innovation and infrastructure
Granular flow and fluidized beds
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon